• Apr 30, 2025

    Newsroom

    Material Information - Update on the Company's IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors

    Learn More

  • Apr 5, 2025

    Newsroom

    PharmaEssentia March 2025 Revenue Report

    Learn More

  • Apr 1, 2025

    Newsroom

    Material Information - The Company Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2b) for PV in Vietnam

    Learn More

  • Jan 2, 2025

    Newsroom

    Material Information - Update on the Company's IND Application ofPhase I Clinical Trial of TCRT-ESO-A2-TW in Patientswith Advanced Solid Tumors to TFDA

    Learn More
/3